Seeing Is Believing: New Approaches For Treating Eye Disorders
Developers of new ophthalmic products are thinking outside of the box. A raft of new gene therapies are progressing in the clinic, including a gene therapy paired with biomimetic goggles. Elsewhere, technology players are partnering with traditional biopharmaceutical companies and bringing algorithms, machine learning and microelectronics to bear on eye disorders and disease diagnostics.
You may also be interested in...
Using the cancer drug off-label to treat wet AMD has been controversial.
Novartis announced it acquired digital therapeutics company Amblyotech, which uses gaming technology with 3-D glasses to help treat lazy eye.
Once the stuff of (largely implausible) science fiction, gene therapy is now a clinical reality and one that is taking an increasing share of the pharma R&D limelight. In Vivo takes a look at how these therapies work, how the field has emerged and where it is likely to go next.